Detalhe da pesquisa
1.
Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer.
Ann Oncol
; 31(10): 1366-1375, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32569727
2.
FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer.
Ann Oncol
; 30(8): 1289-1297, 2019 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31147675
3.
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer.
Ann Oncol
; 30(6): 927-933, 2019 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30903140
4.
Early evolutionary divergence between papillary and anaplastic thyroid cancers.
Ann Oncol
; 29(6): 1454-1460, 2018 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29648575
5.
A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade.
Ann Oncol
; 29(1): 170-177, 2018 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29045543
6.
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.
Ann Oncol
; 29(5): 1203-1210, 2018 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29635390
7.
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.
Ann Oncol
; 28(1): 128-135, 2017 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28177460
8.
Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).
Ann Oncol
; 28(10): 2451-2457, 2017 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28961841
9.
Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer.
Ann Oncol
; 28(6): 1294-1301, 2017 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28368441
10.
Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status.
Ann Oncol
; 26(7): 1494-500, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25851628
11.
Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.
Ann Oncol
; 25(3): 552-563, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24265351
12.
Early evolutionary divergence between papillary and anaplastic thyroid cancers.
Ann Oncol
; 30(11): 1843, 2019 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31406995
13.
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.
Ann Oncol
; 30(6): 1018, 2019 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30624555
14.
Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.
Ann Oncol
; 25(9): 1729-1735, 2014 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-25009010
15.
Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.
Ann Oncol
; 29(11): 2268, 2018 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29718117
16.
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.
Ann Oncol
; 29(10): 2152, 2018 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29701764
17.
Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin.
Nat Commun
; 14(1): 2973, 2023 05 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37221181
18.
The search for simplicity: is this compatible with precision medicine?
Ann Oncol
; 28(1): 10-12, 2017 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28177469
19.
Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer.
NPJ Precis Oncol
; 5(1): 23, 2021 Mar 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-33742063
20.
LOXL2-mediated H3K4 oxidation reduces chromatin accessibility in triple-negative breast cancer cells.
Oncogene
; 39(1): 79-121, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31462706